Aldeyra commences late-stage study of reproxalap in rare inherited skin disorder [Seeking Alpha]
Aldeyra Therapeutics, Inc. (ALDX)
Last aldeyra therapeutics, inc. earnings: 11/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.aldeyra.com/investor-relations
Company Research
Source: Seeking Alpha
Aldeyra commences late-stage study of reproxalap in rare inherited skin disorderEnrollment is underway in a Phase 3 clinical trial evaluating Aldeyra Therapeutics' (ALDX+0.6%) topical dermal reproxalap for the treatment of ichthyosis (thickened, dry scaly skin) in patients withSjögren-Larsson Syndrome (SLS).The primary endpoint of the39-subject study is ichthyosis severity score through week 24. According to ClinicalTrials.gov, the estimated completion date is December 2020.Two years ago, the company announced successful results from a small-scale Phase 2 study. 83% (n=5/6) of treated patients achieved a rating of "almost clear" or "mild" on global assessment. 100% (n=6/6) improved over the course of treatment.Reproxalap is an aldehyde-binding molecule or aldehyde trap. By decreasing aldehyde load, it may mitigate excessive inflammation caused by excess aldehydes.Click to subscribe to real-time analytics on ALDXNow read:Sangamo's Acquisition Of TxCell Is A Double-Edged Sword »Subscrib
Show less
Read more
Impact Snapshot
Event Time:
ALDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALDX alerts
High impacting Aldeyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALDX
News
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024Business Wire
- Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $10.00 price target on the stock.MarketBeat
- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The Corner [Yahoo! Finance]Yahoo! Finance
- Aldeyra Therapeutics, Inc (NASDAQ: ALDX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
ALDX
Earnings
- 8/3/23 - Beat
ALDX
Sec Filings
- 4/17/24 - Form 4/A
- 4/17/24 - Form 4/A
- 4/8/24 - Form 4
- ALDX's page on the SEC website